Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12090340 | 0.86 | DYRK1A (0.48) | KDM4CHTR3ADYRK1AKDM4EALDH1A1 | |
| SCHEMBL12090346 | 0.79 | KDM4C (0.44) | KDM4CKAT2BHTR3ADYRK1ALMNA | |
| SCHEMBL10271492 | 0.76 | HASPIN (0.46) | KDM4CKAT2BHTR3ADYRK1AALDH1A1 | |
| SCHEMBL11897362 | 0.71 | CYP2D6 (0.45) | — | |
| SCHEMBL4782808 | 0.71 | HTR3A (0.55) | KDM4CHTR3ADYRK1ALMNAKDM4E | |
| SCHEMBL25793332 | 0.70 | HTR6 (0.58) | KAT2BHTR3AMTNR1AMTNR1B | |
| SCHEMBL12093544 | 0.69 | PSEN1 (0.39) | — | |
| SCHEMBL7658563 | 0.69 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL8566732 | 0.68 | ALOX5 (0.66) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL12347982 | 0.68 | ADORA2A (0.55) | KDM4CHTR3ADYRK1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | KDM4C 4312/4885KAT2B 2105/4885HTR3A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.